{"pmid":32329275,"title":"[An analysis of global research on SARS-CoV-2].","text":["[An analysis of global research on SARS-CoV-2].","The SARS-CoV-2 has been spread to 26 countries around the world since its outbreak. By February 16, 2020, more than 68 000 people had been diagnosed with COVID-19. Researchers from all over the world have carried out timely studies on this public health emergency and produced a number of scientific publications. This review aims to re-analyze and summarize the current research findings in a timely manner to guide scholars in relevant fields to further SARS-CoV-2 research and assist healthcare professionals in their work and decision-making. The SARS-CoV-2 related terms were selected in both English and Chinese and were searched in several major databases, including Pubmed, Web of Science, CNKI, Wanfang, and VIP databases. The reference list of each search result was screened for relevance, which was further supplemented to the search results. The included studies were categorized by topics with key characteristics extracted, re-analyzed, and summarized. A total of 301 articles were finally included with 136 in Chinese and 165 in English. The number of publications has rapidly increased since mid-January, 2020, and a peak day was 6th February on which 50 articles were published. The top three countries publishing articles were China, the United States and the United Kingdom. The Lancet and its specialty journals have published the most articles, with contribution also from journals such as New England Journal of Medicine ( NEJM), The Journal of the American Medical Association ( JAMA), and Nature. All articles were categorized into epidemiology, clinical diagnosis and treatment, basic research, pregnant women and children, mental health, epidemic prevention & control, and others. The literatures related to SARS-CoV-2 are emerging rapidly. It is necessary to sort out and summarize the research topic in time, which has a good reference value for staff in different positions. At the same time, it is necessary to strengthen the judgment of the quality of literatures.","Sheng Wu Yi Xue Gong Cheng Xue Za Zhi","Zhang, Longhao","Li, Baihong","Jia, Peng","Pu, Jian","Bai, Bei","Li, Yin","Zhu, Peijia","Li, Lei","Zeng, Guojun","Zhao, Xin","Dong, Shanshan","Liu, Menghan","Zhang, Nan","32329275"],"abstract":["The SARS-CoV-2 has been spread to 26 countries around the world since its outbreak. By February 16, 2020, more than 68 000 people had been diagnosed with COVID-19. Researchers from all over the world have carried out timely studies on this public health emergency and produced a number of scientific publications. This review aims to re-analyze and summarize the current research findings in a timely manner to guide scholars in relevant fields to further SARS-CoV-2 research and assist healthcare professionals in their work and decision-making. The SARS-CoV-2 related terms were selected in both English and Chinese and were searched in several major databases, including Pubmed, Web of Science, CNKI, Wanfang, and VIP databases. The reference list of each search result was screened for relevance, which was further supplemented to the search results. The included studies were categorized by topics with key characteristics extracted, re-analyzed, and summarized. A total of 301 articles were finally included with 136 in Chinese and 165 in English. The number of publications has rapidly increased since mid-January, 2020, and a peak day was 6th February on which 50 articles were published. The top three countries publishing articles were China, the United States and the United Kingdom. The Lancet and its specialty journals have published the most articles, with contribution also from journals such as New England Journal of Medicine ( NEJM), The Journal of the American Medical Association ( JAMA), and Nature. All articles were categorized into epidemiology, clinical diagnosis and treatment, basic research, pregnant women and children, mental health, epidemic prevention & control, and others. The literatures related to SARS-CoV-2 are emerging rapidly. It is necessary to sort out and summarize the research topic in time, which has a good reference value for staff in different positions. At the same time, it is necessary to strengthen the judgment of the quality of literatures."],"journal":"Sheng Wu Yi Xue Gong Cheng Xue Za Zhi","authors":["Zhang, Longhao","Li, Baihong","Jia, Peng","Pu, Jian","Bai, Bei","Li, Yin","Zhu, Peijia","Li, Lei","Zeng, Guojun","Zhao, Xin","Dong, Shanshan","Liu, Menghan","Zhang, Nan"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329275","week":"202017|Apr 20 - Apr 26","doi":"10.7507/1001-5515.202002034","keywords":["covid-19","sars-cov-2","bibliometrics","recommended learning list"],"source":"PubMed","weight":0,"locations":["Chinese","Wanfang","Chinese","China","United States","United Kingdom"],"countries":["United States","United Kingdom","China"],"countries_codes":["USA|United States","GBR|United Kingdom","CHN|China"],"_version_":1664996914827886593,"score":8.518259,"similar":[{"pmid":32268923,"pmcid":"PMC7138957","title":"Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis.","text":["Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis.","BACKGROUND: A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China, in late December 2019, and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia. METHODS: We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG), and evaluate risk of bias (YL and DZ). Data analysis will be conducted using the Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g., publication bias) will be investigated using funnel plots, Egger's test and Begg's test, and Trim and Fill analysis. DISCUSSION: This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number: CRD42020168004.","Syst Rev","Li, Yuxi","Liu, Xiaobo","Guo, Liuxue","Li, Juan","Zhong, Dongling","Zhang, Yonggang","Clarke, Mike","Jin, Rongjiang","32268923"],"abstract":["BACKGROUND: A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China, in late December 2019, and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia. METHODS: We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG), and evaluate risk of bias (YL and DZ). Data analysis will be conducted using the Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g., publication bias) will be investigated using funnel plots, Egger's test and Begg's test, and Trim and Fill analysis. DISCUSSION: This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number: CRD42020168004."],"journal":"Syst Rev","authors":["Li, Yuxi","Liu, Xiaobo","Guo, Liuxue","Li, Juan","Zhong, Dongling","Zhang, Yonggang","Clarke, Mike","Jin, Rongjiang"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32268923","week":"202015|Apr 06 - Apr 12","doi":"10.1186/s13643-020-01343-4","keywords":["covid-19","coronavirus","meta-analysis","pneumonia","systematic review","traditional chinese herbal medicine emerging infectious diseases"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Chinese","Chinese","Chinese","Wanfang","Chinese","Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315676372992,"score":268.24387},{"pmid":32314805,"title":"CT imaging features of 4,121 patients with COVID-19: a meta-analysis.","text":["CT imaging features of 4,121 patients with COVID-19: a meta-analysis.","OBJECTIVE: We systematically reviewed the CT imaging features of COVID-19 in order to provide reference for clinical practice. METHODS: Our article comprehensively searched PubMed, FMRS, EMbase, CNKI,WanFang databases and VIP databases to collect literatures about the CT imaging features of COVID-19 from 1 January 2020 to 16 March 2020. Three reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, and then, this meta-analysis was performed by using Stata12.0 software. RESULTS: 34 retrospective studies involving a total of 4 121 COVID-19 patients were included. The results of meta-analysis showed that most patients presented bilateral lung involvement (73.8%, 95%CI: 65.9%-81.1%) or multilobar involvement (67.3%,95%CI: 54.8%-78.7 %) and just a little patients showed normal CT findings (8.4%). We found that the most common changes in lesion density was ground-glass opacities (68.1%,95%CI: 56.9%-78.2%). Other changes in density included air bronchogram sign(44.7%), crazy-paving pattern (35.6%) and consolidation (32.0%). Patchy (40.3%), spider web sign (39.5%), cord-like (36.8%) and nodular (20.5%) were common lesion shapes in COVID-19 patients. Pleural thickening (27.1%) was found in some patients. Lymphadenopathy(5.4%) and pleural effusion (5.3%) were rare. CONCLUSION: The lung lesions of patients with COVID-19 were mostly bilateral lungs or multilobar involved. The most common chest CT findings were patchy and ground-glass opacities. Some patients had air bronchogram, spider web sign and cord-like. Lymphadenopathy and pleural effusion were rare. This article is protected by copyright. All rights reserved.","J Med Virol","Zhu, Jieyun","Zhong, Zhimei","Li, Hongyuan","Ji, Pan","Pang, Jielong","Li, Bocheng","Zhang, Jianfeng","32314805"],"abstract":["OBJECTIVE: We systematically reviewed the CT imaging features of COVID-19 in order to provide reference for clinical practice. METHODS: Our article comprehensively searched PubMed, FMRS, EMbase, CNKI,WanFang databases and VIP databases to collect literatures about the CT imaging features of COVID-19 from 1 January 2020 to 16 March 2020. Three reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, and then, this meta-analysis was performed by using Stata12.0 software. RESULTS: 34 retrospective studies involving a total of 4 121 COVID-19 patients were included. The results of meta-analysis showed that most patients presented bilateral lung involvement (73.8%, 95%CI: 65.9%-81.1%) or multilobar involvement (67.3%,95%CI: 54.8%-78.7 %) and just a little patients showed normal CT findings (8.4%). We found that the most common changes in lesion density was ground-glass opacities (68.1%,95%CI: 56.9%-78.2%). Other changes in density included air bronchogram sign(44.7%), crazy-paving pattern (35.6%) and consolidation (32.0%). Patchy (40.3%), spider web sign (39.5%), cord-like (36.8%) and nodular (20.5%) were common lesion shapes in COVID-19 patients. Pleural thickening (27.1%) was found in some patients. Lymphadenopathy(5.4%) and pleural effusion (5.3%) were rare. CONCLUSION: The lung lesions of patients with COVID-19 were mostly bilateral lungs or multilobar involved. The most common chest CT findings were patchy and ground-glass opacities. Some patients had air bronchogram, spider web sign and cord-like. Lymphadenopathy and pleural effusion were rare. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhu, Jieyun","Zhong, Zhimei","Li, Hongyuan","Ji, Pan","Pang, Jielong","Li, Bocheng","Zhang, Jianfeng"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314805","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25910","keywords":["computed tomography","coronavirus disease 2019","imaging features","meta-analysis","pneumonia","systematical review"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664714520174526464,"score":207.75714},{"pmid":32271460,"title":"Coronavirus disease 2019: a bibliometric analysis and review.","text":["Coronavirus disease 2019: a bibliometric analysis and review.","OBJECTIVE: On December 8, 2019, many cases of pneumonia with unknown etiology were first reported in Wuhan, China, subsequently identified as a novel coronavirus infection aroused worldwide concern. As the outbreak is ongoing, more and more researchers focused interest on the COVID-19. Therefore, we retrospectively analyzed the publications about COVID-19 to summarize the research hotspots and make a review, to provide reference for researchers in the world. MATERIALS AND METHODS: We conducted a search in PubMed using the keywords \"COVID-19\" from inception to March 1, 2020. Identified and analyzed the data included title, corresponding author, language, publication time, publication type, research focus. RESULTS: 183 publications published from 2020 January 14 to 2020 February 29 were included in the study. The first corresponding authors of the publications were from 20 different countries. Among them, 78 (42.6%) from the hospital, 64 (35%) from the university and 39 (21.3%) from the research institution. All the publications were published in 80 different journals. Journal of Medical Virology published most of them (n=25). 60 (32.8%) were original research, 29 (15.8%) were review, 20 (10.9%) were short communications. 68 (37.2%) epidemiology, 49 (26.8%) virology and 26 (14.2%) clinical features. CONCLUSIONS: According to our review, China has provided a large number of research data for various research fields, during the outbreak of COVID-19. Most of the findings play an important role in preventing and controlling the epidemic around the world. With research on the COVID-19 still booming, new vaccine and effective medicine for COVID-19 will be expected to come out in the near future with the joint efforts of researchers worldwide.","Eur Rev Med Pharmacol Sci","Lou, J","Tian, S-J","Niu, S-M","Kang, X-Q","Lian, H-X","Zhang, L-X","Zhang, J-J","32271460"],"abstract":["OBJECTIVE: On December 8, 2019, many cases of pneumonia with unknown etiology were first reported in Wuhan, China, subsequently identified as a novel coronavirus infection aroused worldwide concern. As the outbreak is ongoing, more and more researchers focused interest on the COVID-19. Therefore, we retrospectively analyzed the publications about COVID-19 to summarize the research hotspots and make a review, to provide reference for researchers in the world. MATERIALS AND METHODS: We conducted a search in PubMed using the keywords \"COVID-19\" from inception to March 1, 2020. Identified and analyzed the data included title, corresponding author, language, publication time, publication type, research focus. RESULTS: 183 publications published from 2020 January 14 to 2020 February 29 were included in the study. The first corresponding authors of the publications were from 20 different countries. Among them, 78 (42.6%) from the hospital, 64 (35%) from the university and 39 (21.3%) from the research institution. All the publications were published in 80 different journals. Journal of Medical Virology published most of them (n=25). 60 (32.8%) were original research, 29 (15.8%) were review, 20 (10.9%) were short communications. 68 (37.2%) epidemiology, 49 (26.8%) virology and 26 (14.2%) clinical features. CONCLUSIONS: According to our review, China has provided a large number of research data for various research fields, during the outbreak of COVID-19. Most of the findings play an important role in preventing and controlling the epidemic around the world. With research on the COVID-19 still booming, new vaccine and effective medicine for COVID-19 will be expected to come out in the near future with the joint efforts of researchers worldwide."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Lou, J","Tian, S-J","Niu, S-M","Kang, X-Q","Lian, H-X","Zhang, L-X","Zhang, J-J"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271460","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20712","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315594584064,"score":192.07967},{"pmid":32272396,"pmcid":"PMC7128194","title":"The possible of immunotherapy for COVID-19: A systematic review.","text":["The possible of immunotherapy for COVID-19: A systematic review.","The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.","Int Immunopharmacol","AminJafari, Akram","Ghasemi, Sorayya","32272396"],"abstract":["The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option."],"journal":"Int Immunopharmacol","authors":["AminJafari, Akram","Ghasemi, Sorayya"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272396","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.intimp.2020.106455","keywords":["2019-ncov","covid-19","immunotherapy","interleukin","monoclonal antibody","vaccine"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664637315597729792,"score":187.08109},{"pmid":32328369,"pmcid":"PMC7174863","title":"A Bibliometric Analysis of COVID-19 Research Activity: A Call for Increased Output.","text":["A Bibliometric Analysis of COVID-19 Research Activity: A Call for Increased Output.","BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has impacted many countries across all inhabited continents, and is now considered a global pandemic, due to its high rate of infectivity. Research related to this disease is pivotal for assessing pathogenic characteristics and formulating therapeutic strategies. The aim of this paper is to explore the activity and trends of COVID-19 research since its outbreak in December 2019. METHODS: We explored the PubMed database and the World Health Organization (WHO) database for publications pertaining to COVID-19 since December 2019 up until March 18, 2020. Only relevant observational and interventional studies were included in our study. Data on COVID-19 incidence were extracted from the WHO situation reports. Research output was assessed with respect to gross domestic product (GDP) and population of each country. RESULTS: Only 564 publications met our inclusion criteria. These articles came from 39 different countries, constituting 24% of all affected countries. China produced the greatest number of publications with 377 publications (67%). With respect to continental research activity, Asian countries had the highest research activity with 434 original publications (77%). In terms of publications per million persons (PPMPs), Singapore had the highest number of publications with 1.069 PPMPs. In terms of publications per billion-dollar GDP, Mauritius ranked first with 0.075. CONCLUSION: COVID-19 is a major disease that has impacted international public health on a global level. Observational studies and therapeutic trials pertaining to COVID-19 are essential for assessing pathogenic characteristics and developing novel treatment options.","Cureus","Chahrour, Mohamad","Assi, Sahar","Bejjani, Michael","Nasrallah, Ali A","Salhab, Hamza","Fares, Mohamad","Khachfe, Hussein H","32328369"],"abstract":["BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has impacted many countries across all inhabited continents, and is now considered a global pandemic, due to its high rate of infectivity. Research related to this disease is pivotal for assessing pathogenic characteristics and formulating therapeutic strategies. The aim of this paper is to explore the activity and trends of COVID-19 research since its outbreak in December 2019. METHODS: We explored the PubMed database and the World Health Organization (WHO) database for publications pertaining to COVID-19 since December 2019 up until March 18, 2020. Only relevant observational and interventional studies were included in our study. Data on COVID-19 incidence were extracted from the WHO situation reports. Research output was assessed with respect to gross domestic product (GDP) and population of each country. RESULTS: Only 564 publications met our inclusion criteria. These articles came from 39 different countries, constituting 24% of all affected countries. China produced the greatest number of publications with 377 publications (67%). With respect to continental research activity, Asian countries had the highest research activity with 434 original publications (77%). In terms of publications per million persons (PPMPs), Singapore had the highest number of publications with 1.069 PPMPs. In terms of publications per billion-dollar GDP, Mauritius ranked first with 0.075. CONCLUSION: COVID-19 is a major disease that has impacted international public health on a global level. Observational studies and therapeutic trials pertaining to COVID-19 are essential for assessing pathogenic characteristics and developing novel treatment options."],"journal":"Cureus","authors":["Chahrour, Mohamad","Assi, Sahar","Bejjani, Michael","Nasrallah, Ali A","Salhab, Hamza","Fares, Mohamad","Khachfe, Hussein H"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328369","week":"202017|Apr 20 - Apr 26","doi":"10.7759/cureus.7357","keywords":["bibliometric","coronavirus disease","covid19","novel coronavirus","public health"],"source":"PubMed","weight":0,"locations":["China","Singapore","Mauritius"],"countries":["Singapore","Mauritius","China"],"countries_codes":["SGP|Singapore","MUS|Mauritius","CHN|China"],"_version_":1664996914829983745,"score":186.38077}]}